S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
Log in

LON:INDV - Indivior Share Price, Forecast & News

GBX 41.74
+0.24 (+0.58 %)
(As of 12/9/2019 04:00 PM ET)
Today's Range
40.70
Now: GBX 41.74
42.50
50-Day Range
36.11
MA: GBX 41.01
51.84
52-Week Range
20.98
Now: GBX 41.74
130.55
Volume1.69 million shs
Average Volume2.44 million shs
Market Capitalization£305.01 million
P/E Ratio1.44
Dividend YieldN/A
BetaN/A
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. Read More…

Industry, Sector and Symbol

Industry Drugs - Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1753-217800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£889 million
Cash FlowGBX 144.13 per share
Book ValueGBX 34.50 per share

Profitability

Miscellaneous

Employees915
Market Cap£305.01 million
Next Earnings Date2/12/2020 (Estimated)
OptionableNot Optionable

Receive INDV News and Ratings via Email

Sign-up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.


Indivior (LON:INDV) Frequently Asked Questions

What is Indivior's stock symbol?

Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV."

When is Indivior's next earnings date?

Indivior is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Indivior.

What price target have analysts set for INDV?

4 analysts have issued 1 year price objectives for Indivior's shares. Their forecasts range from GBX 114 to GBX 180. On average, they expect Indivior's share price to reach GBX 143.50 in the next twelve months. This suggests a possible upside of 243.8% from the stock's current price. View Analyst Price Targets for Indivior.

What is the consensus analysts' recommendation for Indivior?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Indivior.

Has Indivior been receiving favorable news coverage?

Media stories about INDV stock have been trending extremely negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Indivior earned a news impact score of -4.0 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the stock's share price in the near term. View News Stories for Indivior.

Who are some of Indivior's key competitors?

What other stocks do shareholders of Indivior own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Futura Medical (FUM), Bigblu Broadband (BBB), Directa Plus (DCTA), Lakehouse (LAKE), Umicore (UMI), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), CityFibre Infrastructure (CITY) and Deltex Medical Group (DEMG).

Who are Indivior's key executives?

Indivior's management team includes the folowing people:
  • Mr. Shaun Thaxter, CEO & Exec. Director
  • Mr. Mark Crossley, CFO & Exec. Director
  • Dr. Christian Heidbreder, Chief Scientific Officer
  • Mr. Ingo Elfering, Chief Information & Innovation Officer
  • Mr. Jason Thompson, VP of Investor Relations

How do I buy shares of Indivior?

Shares of INDV and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Indivior's stock price today?

One share of INDV stock can currently be purchased for approximately GBX 41.74.

How big of a company is Indivior?

Indivior has a market capitalization of £305.01 million and generates £889 million in revenue each year. Indivior employs 915 workers across the globe.View Additional Information About Indivior.

What is Indivior's official website?

The official website for Indivior is http://indivior.com/.

How can I contact Indivior?

Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company can be reached via phone at +44-1753-217800.


MarketBeat Community Rating for Indivior (LON INDV)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  504 (Vote Outperform)
Underperform Votes:  249 (Vote Underperform)
Total Votes:  753
MarketBeat's community ratings are surveys of what our community members think about Indivior and other stocks. Vote "Outperform" if you believe INDV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INDV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel